[CLAIMS]

1. A cyclic compound represented by formula (1) below or a salt thereof, or a solvate thereof:



(1)

wherein:

L_1 is a single bond, or is $-CHM_1-$, $-(CH_2)_nS(CH_2)_m-$, $-(CH_2)_nS(O)(CH_2)_m-$, or $-(CH_2)_nS(O)_2(CH_2)_m-$, wherein n and m are each independently 1 or 2,

R_1 is any of (a1) to (a6) below:

(a1) R_1 is hydrogen, C_1-C_7 alkyl, C_2-C_7 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxyC_1-C_6 alkyl, C_2-C_6 alkenyloxyC_1-C_6 alkyl, C_1-C_6 alkylthioC_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkylC_1-C_6 alkyl, C_3-C_8 cycloalkoxyC_1-C_6 alkyl, C_7-C_{14} aralkyl, or 5- to 10-membered heteroarylC_1-C_6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, C_1-C_6 alkyl, aminocarbonyl (wherein the amino is $-NH_2$, mono-C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, or 4- to 8-membered cyclic amino), and C_1-C_6 alkylsulfonyl;

(a2) R_1, together with P_1, the carbon atom to which R_1 is bonded, and the nitrogen atom to which P_1 is bonded, forms a 4- to 7-membered saturated heterocyclic ring;

(a3) R_1, together with Q_1 and the carbon atom to which R_1 and Q_1 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;

(a4) R_1, together with M_1, the carbon atom to which R_1 is bonded, and the carbon atom to which M_1 is bonded, forms a 3- to 8-membered alicyclic ring;

(a5) R_1, together with R_5, forms a divalent group selected from the group consisting of C_1-C_{10} alkylene, C_2-C_{10} alkenylene, C_2-C_{10} alkynylene, C_3-C_8 cycloalkylene, C_6-C_{10} arylene, $-CO-NR_A-$, $-NR_A-CO-$, and a combination of two or more of these, wherein one or more carbon atoms constituting the divalent group are optionally substituted with one or more heteroatoms

independently selected from the group consisting of N, O, and S, the divalent group is optionally substituted with one or more groups independently selected from the group consisting of halogen and C_1-C_6 alkyl, and R_A is hydrogen or C_1-C_6 alkyl; or

(a6) R_1, together with R_9, forms a divalent group selected from the group consisting of C_1-C_{10} alkylene, C_2-C_{10} alkenylene, C_2-C_{10} alkynylene, C_3-C_8 cycloalkylene, C_6-C_{10} arylene, -CO-NR_B-, -NR_B-CO-, and a combination of two or more of these, wherein one or more carbon atoms constituting the divalent group is optionally substituted with one or more heteroatoms independently selected from the group consisting of N, O, and S, the divalent group is optionally substituted with one or more groups independently selected from the group consisting of halogen and C_1-C_6 alkyl, and R_B is hydrogen or C_1-C_6 alkyl;

P_1, except when R_1 and P_1 form a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C_1-C_6 alkyl, wherein the C_1-C_6 alkyl is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and aminocarbonyl (wherein the amino is -NH_2, mono-C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, or 4- to 8-membered cyclic amino),

Q_1, except when R_1 and Q_1 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C_1-C_6 alkyl, and

M_1, except when R_1 and M_1 form a 3- to 8-membered alicyclic ring, is hydrogen or C_1-C_6 alkyl,

R_2 is any of (b1) to (b4) below:

(b1) R_2 is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxyC_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkylC_1-C_6 alkyl, C_3-C_8 cycloalkoxyC_1-C_6 alkyl, or 4- to 7-membered heterocyclyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, and C_1-C_6 alkylsulfonyl;

(b2) R_2, together with P_2, the carbon atom to which R_2 is bonded, and the nitrogen atom to which P_2 is bonded, forms a 4- to 7-membered saturated heterocyclic ring;

(b3) R_2, together with Q_2 and the carbon atom to which R_2 and Q_2 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or

(b4) R_2, together with R_{11}, forms a divalent group selected from the group consisting of C_1-C_{10} alkylene, C_2-C_{10} alkenylene, C_2-C_{10} alkynylene, C_3-C_8 cycloalkylene, C_6-C_{10} arylene, -CO-NR_C-, -NR_C-CO-, -C_3-C_8 alkylene-NR_C-, -C_3-C_8 alkenylene-NR_C-, and a combination of two or more of these, wherein one or more carbon atoms constituting the divalent group are optionally substituted with one or more heteroatoms independently selected from the group consisting of N, O, and S, the divalent group is optionally substituted with one or more groups independently selected from the group consisting of halogen and C_1-C_6 alkyl, and R_C is hydrogen or C_1-C_6 alkyl;

P_2, except when R_2 and P_2 form a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C_1-C_6 alkyl, wherein the C_1-C_6 alkyl is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and aminocarbonyl (wherein the amino is -NH_2, mono-C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, or 4- to 8-membered cyclic amino),

Q_2, except when R_2 and Q_2 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C_1-C_6 alkyl,

R_3 is any of (c1) to (c3) below:

(c1) R_3 is hydrogen, C_1-C_6 alkyl, C_1-C_6 alkoxyC_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkylC_1-C_6 alkyl, C_3-C_8 cycloalkoxyC_1-C_6 alkyl, or C_7-C_{14} aralkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of hydroxy and aminocarbonyl (wherein the amino is -NH_2, mono-C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, or 4- to 8-membered cyclic amino);

(c2) R_3, together with P_3, the carbon atom to which R_3 is bonded, and the nitrogen atom to which P_3 is bonded, forms a 4- to 7-membered saturated heterocyclic ring, wherein the 4- to 7-membered saturated heterocyclic ring is optionally substituted with one or more groups selected from the group consisting of C_1-C_6 alkyl and C_1-C_6 alkoxy; or

(c3) R_3, together with Q_3 and the carbon atom to which R_3 and Q_3 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;

P_3, except when R_3 and P_3 form a 4- to 7-membered saturated heterocyclic ring, is hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxyC_1-C_6 alkyl, or C_3-C_8 cycloalkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, C_1-C_6 alkoxy, and C_1-C_6 aminoalkyl (wherein the amino is -NH_2, mono-C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, or 4- to 8-membered cyclic amino, and the 4- to 8-membered cyclic amino is optionally substituted with one or more halogen atoms),

Q_3, except when R_3 and Q_3 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C_1-C_6 alkyl,

R_4 is any of (d1) to (d4) below:

(d1) R_4 is hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_6 alkoxyC_1-C_6 alkyl, C_2-C_6 alkenyloxyC_1-C_6 alkyl, or C_1-C_6 carboxyalkyl, each of which is optionally substituted with one or more hydroxy groups;

(d2) R_4, together with P_4, the carbon atom to which R_4 is bonded, and the nitrogen atom to which P_4 is bonded, forms a 4- to 7-membered saturated heterocyclic ring, wherein the 4- to 7-membered saturated heterocyclic ring is optionally substituted with one or more C_1-C_6 alkyl groups;

(d3) R_4, together with Q_4 and the carbon atom to which R_4 and Q_4 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or

(d4) R_4, together with P_5, forms a divalent group selected from the group consisting of C_1-C_{10} alkylene, C_2-C_{10} alkenylene, C_2-C_{10} alkynylene, C_3-C_8 cycloalkylene, 3- to 7-membered heterocyclylene, C_6-C_{10} arylene, -CO-NR_D-, -NR_D-CO-, and a combination of two or more of these, wherein one or more carbon atoms constituting the divalent group are optionally substituted with one or more heteroatoms independently selected from the group consisting of N, O, and S, the divalent group is optionally substituted with one or more groups independently selected from the group consisting of halogen and C_1-C_6 alkyl, and R_D is hydrogen or C_1-C_6 alkyl;

P_4, except when R_4 and P_4 form a 4- to 7-membered saturated heterocyclic ring, is any of (e1) to (e2) below:

(e1) P_4 is hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_1-C_6 alkoxyC_1-C_6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and aminocarbonyl (wherein the amino is -NH_2, mono-C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, or 4- to 8-membered cyclic amino); or

(e2) P_4, together with P_5, forms a divalent group selected from the group consisting of C_1-C_{10} alkylene, C_2-C_{10} alkenylene, C_2-C_{10} alkynylene, C_3-C_8 cycloalkylene, C_6-C_{10} arylene, -CO-NR_E-, -NR_E-CO-, and a combination of two or more of these, wherein one or more carbon atoms constituting the divalent group are optionally substituted with one or more heteroatoms independently selected from the group consisting of N, O, and S, the divalent group is optionally substituted with one or more groups independently selected from the group consisting of halogen and C_1-C_6 alkyl, and R_E is hydrogen or C_1-C_6 alkyl;

Q_4, except when R_4 and Q_4 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C_1-C_6 alkyl,

R_5, except when R_1 and R_5 form a divalent group, is any of (f1) to (f4) below:

(f1) R_5 is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkenyloxycarbonylC_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 alkoxyC_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkylC_1-C_6 alkyl, C_3-C_8 cycloalkoxyC_1-C_6 alkyl, C_7-C_{14} aralkyl, C_6-C_{10} aryloxyC_1-C_6 alkyl, C_7-C_{14} aralkoxyC_1-C_6 alkyl, or 5- to 10-membered heteroarylC_1-C_6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyloxy, C_1-C_6 haloalkoxy, cyano, and C_1-C_6 alkylsulfonyl, C_2-C_6 alkenyl, C_3-C_8 cycloalkyl, and C_1-C_6 alkylcarbonyl; or

(f2) R_5, together with R_8, forms C_4-C_8 alkylene;

(f3) R_5, together with P_5, the carbon atom to which R_5 is bonded, and the nitrogen atom to which P_5 is bonded, forms a 4- to 7-membered saturated heterocyclic ring; or

(f4) R_5, together with Q_5 and the carbon atom to which R_5 and Q_5 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;

P_5, except when R_5 and P_5 form a 4- to 7-membered saturated heterocyclic ring, except when R_4 and P_5 form a divalent group, and except when P_4 and P_5 form a divalent group, is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxyC_1-C_6 alkyl, or C_3-C_8 cycloalkylC_1-C_6 alkyl, wherein the C_1-C_6 alkyl is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, aminocarbonyl (wherein the amino is -NH_2, mono-C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, or 4- to 8-membered cyclic amino), and amino,

Q_5, except when R_5 and Q_5 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C_1-C_6 alkyl,

R_6 is any of (g1) to (g3) below:

(g1) R_6 is hydrogen or C_1-C_6 alkyl;

(g2) R_6, together with P_6, the carbon atom to which R_6 is bonded, and the nitrogen atom to which P_6 is bonded, forms a 4- to 7-membered saturated heterocyclic ring; or

(g3) R_6, together with Q_6 and the carbon atom to which R_6 and Q_6 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;

P_6, except when R_6 and P_6 form a 4- to 7-membered saturated heterocyclic ring, is C_1-C_6 alkyl or C_3-C_8 cycloalkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and aminocarbonyl (wherein the amino is -NH_2, mono-C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, or 4- to 8-membered cyclic amino),

Q_6, except when R_6 and Q_6 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C_1-C_6 alkyl,

R_7 is any of (h1) to (h6) below:

(h1) R_7 is C_6-C_{10} aryloxyC_1-C_6 alkyl, C_7-C_{14} aralkyl, C_7-C_{14} aralkoxyC_1-C_6 alkyl, or 5- to 10-membered heteroarylC_1-C_6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, cyano, C_1-C_6 alkylsulfonyl, SF_5, and C_3-C_8 cycloalkyl;

(h2) R_7, together with P_7, the carbon atom to which R_7 is bonded, and the nitrogen atom to which P_7 is bonded, forms a 4- to 7-membered saturated heterocyclic ring; or

(h3) R_7, together with Q_7 and the carbon atom to which R_7 and Q_7 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;

P_7, except when R_7 and P_7 form a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C_1-C_6 alkyl, wherein the C_1-C_6 alkyl is optionally substituted with one or more

groups independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and aminocarbonyl (wherein the amino is -NH_2, mono-C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, or 4- to 8-membered cyclic amino),

Q_7, except when R_7 and Q_7 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C_1-C_6 alkyl,

R_8, except when R_5 and R_8 form C_4-C_8 alkylene, is any of (i1) to (i3) below:

(i1) R_8 is hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxyC_1-C_6 alkyl, C_2-C_6 alkenyloxycarbonylC_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkylC_1-C_6 alkyl, C_6-C_{10} aryloxyC_1-C_6 alkyl, C_7-C_{14} aralkyl, C_7-C_{14} aralkoxyC_1-C_6 alkyl, 5- to 10-membered heteroarylC_1-C_6 alkyl, or 5- to 10-membered heteroarylC_1-C_6 alkoxyC_1-C_6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, carboxy, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, cyano, aminocarbonyl (wherein the amino is -NH_2, mono-C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), 4- to 7-membered heterocycloalkylidene, protected 4- to 7-membered heterocycloalkylidene, 4- to 7-membered heterocyclyl, and protected 4- to 7-membered heterocyclyl;

(i2) R_8, together with P_8, the carbon atom to which R_8 is bonded, and the nitrogen atom to which P_8 is bonded, forms a 4- to 7-membered saturated heterocyclic ring, wherein the 4- to 7-membered saturated heterocyclic ring is optionally condensed with a saturated carbon ring or an aromatic ring, the 4- to 7-membered saturated heterocyclic ring is optionally substituted with one or more halogen atoms, oxo, one or more C_1-C_6 alkyl groups, C_1-C_6 haloalkyl, C_3-C_8 spirocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, 4- to 8-membered cyclic amino (wherein the cyclic amino is optionally substituted with one or more halogen atoms), or OS_8, and S_8 is hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 hydroxyalkyl, C_3-C_8 cycloalkylC_1-C_6 alkyl, 4- to 7-membered heterocyclyl, C_7-C_{14} aralkyl (wherein the aralkyl is optionally substituted with one or more halogen atoms, C_1-C_6 alkyl, C_1-C_6 alkoxy, or C_1-C_6 haloalkoxy), 5- to 10-membered heteroarylC_1-C_6 alkyl, or C_3-C_8 cycloalkyl; or

(i3) R_8, together with Q_8 and the carbon atom to which R_8 and Q_8 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;

P_8, except when R_8 and P_8 form a 4- to 7-membered saturated heterocyclic ring, is hydrogen, C_1-C_6 alkyl, C_1-C_6 alkoxyC_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_6 alkoxyC_2-C_6 alkenyl, C_3-C_8 cycloalkyl, 4- to 7-membered heterocyclyl, 4- to 7-membered heterocyclylC_1-C_6 alkyl, C_6-C_{10} aryl, C_7-C_{14} aralkyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroarylC_1-C_6 alkyl, each of which is optionally substituted with one or more groups independently selected from the

group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and aminocarbonyl (wherein the amino is -NH_2, mono-C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, or 4- to 8-membered cyclic amino),

Q_8, except when R_8 and Q_8 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C_1-C_6 alkyl,

R_9, except when R_1 and R_9 form a divalent group, is any of (j1) to (j3) below:

(j1) R_9 is hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_6 alkoxyC_1-C_6 alkyl, C_2-C_6 alkenyloxyC_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkylC_1-C_6 alkyl, C_7-C_{14} aralkyl, or 5- to 10-membered heteroarylC_1-C_6 alkoxyC_1-C_6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, aminocarbonyl (wherein the amino is -NH_2, mono-C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, or 4- to 8-membered cyclic amino), and C_1-C_6 alkylsulfonyl;

(j2) R_9, together with P_9, the carbon atom to which R_9 is bonded, and the nitrogen atom to which P_9 is bonded, forms a 4- to 7-membered saturated heterocyclic ring; or

(j3) R_9, together with Q_9 and the carbon atom to which R_9 and Q_9 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, each of which is optionally substituted with one or more halogen atoms or one or more C_1-C_6 alkyl groups;

P_9, except when R_9 and P_9 form a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C_1-C_6 alkyl, wherein the C_1-C_6 alkyl is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and aminocarbonyl (wherein the amino is -NH_2, mono-C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, or 4- to 8-membered cyclic amino),

Q_9, except when R_9 and Q_9 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C_1-C_6 alkyl,

R_{10} is any of (k1) to (k3) below:

(k1) R_{10} is C_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 alkoxyC_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkylC_1-C_6 alkyl, C_3-C_8 cycloalkoxyC_1-C_6 alkyl, or C_7-C_{14} aralkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, and C_1-C_6 alkylsulfonyl;

(k2) R_{10}, together with P_{10}, the carbon atom to which R_{10} is bonded, and the nitrogen atom to which P_{10} is bonded, forms a 4- to 7-membered saturated heterocyclic ring; or

(k3) R_{10}, together with Q_{10} and the carbon atom to which R_{10} and Q_{10} are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;

P_{10}, except when R_{10} and P_{10} form a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C_1-C_6 alkyl, wherein the C_1-C_6 alkyl is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and

aminocarbonyl (wherein the amino is -NH_2, mono-C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, or 4- to 8-membered cyclic amino),

Q_{10}, except when R_{10} and Q_{10} form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C_1-C_6 alkyl, and

L_{11} is a single bond, or is -CHM_{11}-, -$(CH_2)_nS(CH_2)_m$-, -$(CH_2)_nS(O)(CH_2)_m$-, or -$(CH_2)_nS(O)_2(CH_2)_m$-, wherein n and m are each independently 1 or 2,

R_{11}, except when R_2 and R_{11} form a divalent group, is any of (l1) to (l5) below:

(l1) R_{11} is hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxyC_1-C_6 alkyl, C_7-C_{14} aralkyl, aminocarbonyl (wherein the amino is -NH_2, mono C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, N-C_1-C_6 alkyl-N-C_2-C_6 alkenylamino, or 4- to 8-membered cyclic amino), or C_3-C_8 cycloalkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, oxo, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, 4- to 7-membered heterocyclyl, aminocarbonyl (wherein the amino is -NH_2, mono-C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, or 4- to 8-membered cyclic amino), and C_1-C_6 alkylsulfonyl;

(l2) R_{11} is a peptide chain containing 1 to 4 amino acid residues;

(l3) R_{11}, together with P_{11}, the carbon atom to which R_{11} is bonded, and the nitrogen atom to which P_{11} is bonded, forms a 4- to 7-membered saturated heterocyclic ring;

(l4) R_{11}, together with Q_{11} and the carbon atom to which R_{11} and Q_{11} are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or

(l5) R_{11}, together with M_{11}, the carbon atom to which R_{11} is bonded, and the carbon atom to which M_{11} is bonded, forms a 3- to 8-membered alicyclic ring;

P_{11}, except when R_{11} and P_{11} form a 4- to 7-membered saturated heterocyclic ring, is hydrogen, C_1-C_6 alkyl, C_3-C_8 cycloalkylC_1-C_6 alkyl, or C_7-C_{14} aralkyl, wherein the C_1-C_6 alkyl is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and aminocarbonyl (wherein the amino is -NH_2, mono-C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, or 4- to 8-membered cyclic amino),

Q_{11}, except when R_{11} and Q_{11} form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C_1-C_6 alkyl, and

M_{11}, except when R_{11} and M_{11} form a 3- to 8-membered alicyclic ring, is hydrogen, and

at least three of P_1 to P_{11} are not hydrogen.

2. The cyclic compound or salt thereof, or solvate thereof according to claim 1, wherein:

(a) R_4 and P_5 together form a divalent group, wherein the divalent group is *-C_3-C_8 alkylene-#, *-C_3-C_8 alkenylene-#, *-C_1-C_3 alkylene-C_3-C_8 cycloalkylene-C_1-C_3 alkylene-#, *-C_1-C_3 alkylene-O-C_3-C_6 alkenylene-#, *-C_1-C_3 alkylene-CO-NR_D-C_1-C_3 alkylene-#, or *-C_1-C_3

alkylene-NR_D-CO-C_1-C_3 alkylene-#, or *-C_1-C_3 alkylene-3- to 7-membered heterocyclylene-C_1-C_3 alkylene-#, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen and C_1-C_6 alkyl, and R_D is hydrogen or methyl,

* means a point of bonding with the carbon atom to which R_4 is bonded, and

means a point of bonding with the nitrogen atom to which P_5 is bonded, or

(b) P_4 and P_5 together form a divalent group, wherein the divalent group is C_3-C_8 alkylene or C_3-C_8 alkenylene, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen and C_1-C_6 alkyl, or

(c) P_5 is C_3-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxyC_1-C_6 alkyl, C_3-C_8 cycloalkylC_1-C_6 alkyl, or C_1-C_6 aminoalkyl.

3. The cyclic compound or salt thereof, or solvate thereof according to claim 1 or 2, wherein R_4 and P_5 together form a divalent group, and a partial structure *-CR_4Q_4-CO-NP_5-* in the cyclic compound represented by formula (1) is represented by a formula below:


,

,

,


, or


wherein:

Y_{11} is hydrogen, C_1-C_6 alkyl, or halogen,

Y_{12} is hydrogen, C_1-C_6 alkyl, or halogen,

Y_{13} is hydrogen, C_1-C_6 alkyl, or halogen, or

Y_{13}, together with Y_{15}, forms C_3-C_8 alkylene or -O-,

Y_{14} is hydrogen or C_1-C_6 alkyl,

Y_{15}, except when Y_{13} and Y_{15} form C_3-C_8 alkylene or -O-, is hydrogen, C_1-C_6 alkyl, or halogen,

Y_{16} is hydrogen or C_1-C_6 alkyl,

Y_{17} is hydrogen or C_1-C_6 alkyl,

Y_{18} is hydrogen or C_1-C_6 alkyl,
R_D is hydrogen or C_1-C_6 alkyl,
n is 0, 1, or 2,
m is 0, 1, or 2, and
* means a point of bonding with an adjacent atom.

4. The cyclic compound or salt thereof, or solvate thereof according to any one of claims 1 to 3, wherein:

R_1 and R_5 together form a divalent group, wherein the divalent group is *-C_1-C_8 alkylene-C_6-C_{10} arylene-C_1-C_3 alkylene-#, *-C_1-C_8 alkylene-O-C_6-C_{10} arylene-C_1-C_3 alkylene-#, *-C_2-C_8 alkenylene-O-C_6-C_{10} arylene-C_1-C_3 alkylene-#, or *-C_2-C_8 alkenylene-C_6-C_{10} arylene-C_1-C_3 alkylene-#, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen and C_1-C_6 alkyl,

* means a point of bonding with the carbon atom to which R_1 is bonded, and
# means a point of bonding with the carbon atom to which R_5 is bonded.

5. The cyclic compound or salt thereof, or solvate thereof according to any one of claims 1 to 3, wherein:

R_1 and R_9 together form a divalent group, wherein the divalent group is *-C_3-C_8 alkylene-#, *-C_3-C_8 alkenylene-#, or *-C_1-C_3 alkylene-O-C_1-C_8 alkylene-#, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, C_1-C_6 alkyl, C_3-C_8 spirocycloalkyl, and 4- to 10-membered spiroheterocyclyl,

* means a point of bonding with the carbon atom to which R_1 is bonded, and
# means a point of bonding with the carbon atom to which R_9 is bonded.

6. The cyclic compound or salt thereof, or solvate thereof according to any one of claims 1 to 5, wherein:

R_2 and R_{11} together form a divalent group, wherein the divalent group is *-C_3-C_8 alkylene-NR_C-# or *-C_3-C_8 alkenylene-NR_C-#, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, C_1-C_6 alkyl, C_3-C_8 spirocycloalkyl, and 4- to 10-membered spiroheterocyclyl, and R_C is hydrogen or methyl,

* means a point of bonding with the carbon atom to which R_2 is bonded, and
# means a point of bonding with the carbon atom to which R_{11} is bonded.

7. The cyclic compound or salt thereof, or solvate thereof according to any one of claims 2 to 6, wherein:

L_1 is a single bond, -CH_2-, or -CH_2-S-CH_2-; and/or

except when R_1 and R_5 together form a divalent group, and except when R_1 and R_9 together form a divalent group, R_1 is C_1-C_7 alkyl optionally substituted with di-C_1-C_6 alkylaminocarbonyl; C_1-C_6 haloalkyl; C_1-C_6 hydroxyalkyl; C_2-C_7 alkenyl; C_2-C_6 alkynyl; C_1-C_6 alkoxyC_1-C_6 alkyl optionally substituted with one or more halogen atoms; C_2-C_6 alkenyloxyC_1-C_6 alkyl; C_1-C_6 alkylthioC_1-C_6 alkyl; C_7-C_{14} aralkyl optionally substituted with one or more halogen atoms, C_1-C_6 alkyl, or cyano; 5- to 10-membered heteroarylC_1-C_6 alkyl; C_3-C_8 cycloalkyl; C_3-C_8 cycloalkylC_1-C_6 alkyl; or C_3-C_8 cycloalkoxyC_1-C_6 alkyl; and/or

R_1 and P_1, together with the nitrogen atom to which P_1 is bonded and the carbon atom to which R_1 is bonded, form a 4- to 7-membered saturated heterocyclic ring; and/or

P_1 is hydrogen or C_1-C_6 alkyl; and/or

Q_1 is hydrogen or methyl; and/or

except when R_2 and R_{11} together form a divalent group, R_2 is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_6 haloalkyl, C_1-C_6 hydroxyalkyl, C_3-C_8 cycloalkyl optionally substituted with one or more halogen atoms, C_1-C_6 alkoxyC_1-C_6 alkyl, or 4- to 7-membered heterocyclyl; and/or

P_2 is hydrogen; and/or

Q_2 is hydrogen, and/or

R_3 is hydrogen, C_1-C_6 alkyl, or C_7-C_{14} aralkyl; and/or

R_3 and P_3, together with the nitrogen atom to which P_3 is bonded and the carbon atom to which R_3 is bonded, form a 4- to 7-membered saturated heterocyclic ring, and the 4- to 7-membered saturated heterocyclic ring is optionally substituted with one or more C_1-C_6 alkyl groups or with C_1-C_6 alkoxy; and/or

R_3 and Q_3, together with the carbon atom to which they are bonded, form a 3- to 8-membered alicyclic ring; and/or

P_3 is hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 cyanoalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_8 cycloalkyl, or C_1-C_6 alkoxyC_1-C_6 alkyl; and/or

Q_3 is hydrogen or methyl; and/or

except when R_4 and P_5 together form a divalent group, R_4 is hydrogen, C_1-C_6 alkyl, C_1-C_6 hydroxyalkyl, C_2-C_6 alkenyl, C_1-C_6 alkoxyC_1-C_6 alkyl, C_2-C_6 alkenyloxyC_1-C_6 alkyl, or C_1-C_6 carboxyalkyl; and/or

R_4 and P_4, together with the nitrogen atom to which P_4 is bonded and the carbon atom to which R_4 is bonded, form a 4- to 7-membered saturated heterocyclic ring, and the 4- to 7-membered saturated heterocyclic ring is optionally substituted with C_1-C_6 alkyl; and/or

except when P_4 and P_5 together form a divalent group, P_4 is C_1-C_6 alkyl or C_1-C_6 alkenyl; and/or

Q_4 is hydrogen; and/or

except when R_5 and R_1 together form a divalent group, R_5 is C_2-C_6 alkynyl; C_2-C_6 alkenyloxycarbonylC_1-C_6 alkyl; C_3-C_8 cycloalkyl; C_3-C_8 cycloalkylC_1-C_6 alkyl optionally substituted with one or more halogen atoms; C_7-C_{14} aralkyl optionally substituted with one or more groups selected from the group consisting of halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, C_2-C_6 alkenyloxy, C_2-C_6 alkenyl, C_3-C_8 cycloalkyl, and C_1-C_6 alkylcarbonyl; 5- to 10-membered heteroarylC_1-C_6 alkyl; C_3-C_8 cycloalkoxyC_1-C_6 alkyl; or C_1-C_6 alkoxyC_1-C_6 alkyl; and/or

Q_5 is hydrogen; and/or

R_6 is hydrogen or C_1-C_6 alkyl; and/or

R_6 and P_6, together with the nitrogen atom to which P_6 is bonded and the carbon atom to which R_6 is bonded, form a 4- to 7-membered saturated heterocyclic ring; and/or

P_6 is C_1-C_6 alkyl; and/or

Q_6 is hydrogen; and/or

R_7 is C_7-C_{14} aralkyl optionally substituted with one or more groups independently selected from the group consisting of halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, C_1-C_6 alkoxy, and C_3-C_8 cycloalkyl; or 5- to 10-membered heteroarylC_1-C_6 alkyl optionally substituted with one or more groups independently selected from the group consisting of halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, C_1-C_6 alkoxy, and C_3-C_8 cycloalkyl; and/or

P_7 is hydrogen; and/or

Q_7 is hydrogen; and/or

R_8 is hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxyC_1-C_6 alkyl, or C_3-C_8 cycloalkylC_1-C_6 alkyl; and/or

R_8 and P_8, together with the nitrogen atom to which P_8 is bonded and the carbon atom to which R_8 is bonded, form a 4- to 7-membered saturated heterocyclic ring, the 4- to 7-membered saturated heterocyclic ring is optionally condensed with a 3- to 8-membered saturated carbocyclic ring, and the 4- to 7-membered saturated heterocyclic ring is optionally substituted with one or more halogen atoms; one or more C_1-C_6 alkyl groups; C_1-C_6 haloalkyl; hydroxy; 4- to 7-membered heterocyclyloxy; oxo; C_1-C_6 alkoxy; C_3-C_8 cycloalkylC_1-C_6 alkoxy; C_1-C_6 haloalkoxy; 4- to 8-membered cyclic amino optionally substituted with one or more halogen atoms; C_3-C_8 spirocycloalkyl; or C_3-C_8 cycloalkoxy; and/or

P_8 is hydrogen or C_1-C_6 alkyl; and/or

Q_8 is hydrogen or methyl; and/or

except when R_9 and R_1 together form a divalent group, R_9 is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_6 alkoxyC_1-C_6 alkyl, C_1-C_6 alkenyloxyC_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkylC_1-C_6 alkyl, or C_7 to C_{14} aralkyl; and/or

R_9 and Q_9, together with the carbon atom to which they are bonded, form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, wherein the 3- to 8-membered alicyclic ring or 4- to 7-membered saturated heterocyclic ring is optionally substituted with one or more halogen atoms or one or more C_1-C_6 alkyl groups; and/or

P_9 is hydrogen or C_1-C_6 alkyl; and/or

Q_9 is hydrogen or methyl; and/or

R_{10} is C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxyC_1-C_6 alkyl, C_3-C_8 cycloalkyl, or C_3-C_8 cycloalkylC_1-C_6 alkyl; and/or

P_{10} is hydrogen or C_1-C_6 alkyl; and/or

Q_{10} is hydrogen or methyl; and/or

L_{11} is $-CH_2-$ or $-CH_2-S-CH_2-$; and/or

except when R_{11} and R_2 together form a divalent group, R_{11} is C_1-C_6 alkyl; di-C_1-C_6 alkylaminocarbonyl; N-C_1-C_6 alkyl-N-C_2-C_6 alkenylaminocarbonyl; N-C_1-C_6 alkyl-N-C_1-C_6 alkoxyC_1-C_6 alkylaminocarbonyl; cyclic aminocarbonyl optionally substituted with one or more C_1-C_6 alkyl groups or 4- to 7-membered heterocyclyl; or C_3-C_8 cycloalkyl; and/or

R_{11} and P_{11}, together with the nitrogen atom to which P_{11} is bonded and the carbon atom to which R_{11} is bonded, form a 4- to 7-membered saturated heterocyclic ring; and/or

P_{11} is hydrogen, C_1-C_6 alkyl, C_3-C_8 cycloalkylC_1-C_6 alkyl, or C_7-C_{14} aralkyl; and/or

Q_{11} is hydrogen; and/or

at least four, five, or six of P_1 to P_{11} are not hydrogen.

8. A pharmaceutical composition comprising the cyclic compound or salt thereof, or solvate thereof according to any one of claims 1 to 7.

9. Use of a pharmaceutical composition in the manufacture of a medicament for selectively inhibiting KRAS in a subject, wherein the pharmaceutical composition comprises the cyclic compound or salt thereof, or solvate thereof according to any one of claims 1 to 7.

10. An oligopeptide compound represented by formula (2) below or a salt thereof, or a solvate thereof:



（2）

wherein:

A_1 is hydrogen, an amino protecting group, an amino acid residue, or a peptide residue,

A_2 is hydroxy, an -O-carboxyl protecting group, an amino acid residue optionally supported on a resin for solid-phase synthesis, a peptide residue optionally supported on a resin for solid-phase synthesis, or a resin for solid-phase synthesis,

wherein, when A_1 and A_2 are amino acid residues and/or peptide residues, A_1 and A_2 are optionally connected,

R_{12} and P_{13} together form a divalent group selected from the group consisting of C_1-C_{10} alkylene, C_2-C_{10} alkenylene, C_2-C_{10} alkynylene, C_3-C_8 cycloalkylene, 3- to 7-membered heterocyclylene, C_6-C_{10} arylene, -CO-NR_F-, -NR_F-CO-, and a combination of two or more of these, wherein one or more carbon atoms constituting the divalent group is optionally substituted with one or more heteroatoms independently selected from the group consisting of N, O, and S, the divalent group is optionally substituted with one or more groups independently selected from the group consisting of halogen and C_1-C_6 alkyl, two different carbon atoms in the divalent group are optionally crosslinked by C_1-C_6 alkylene, and R_F is hydrogen or C_1-C_6 alkyl,

P_{12} is C_1-C_6 alkyl,

Q_{12} is hydrogen or C_1-C_6 alkyl,

R_{13} is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkenyloxycarbonylC_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 alkoxyC_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkylC_1-C_6 alkyl, C_3-C_8 cycloalkoxyC_1-C_6 alkyl, C_7-C_{14} aralkyl, C_6-C_{10} aryloxyC_1-C_6 alkyl, C_7-C_{14} aralkoxyC_1-C_6 alkyl, or 5- to 10-membered heteroarylC_1-C_6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyloxy, C_1-C_6 haloalkoxy, cyano, C_1-C_6 alkylsulfonyl, C_2-C_6 alkenyl, C_3-C_8 cycloalkyl, and C_1-C_6 alkylcarbonyl,

Q_{13} is hydrogen or C_1-C_6 alkyl,

R_{14} is hydrogen or C_1-C_6 alkyl,

P_{14} is C_1-C_6 alkyl, and

Q_{14} is hydrogen or C_1-C_6 alkyl.

11. The oligopeptide compound or salt thereof, or solvate thereof according to claim 10, wherein:

R_{12} and P_{13} together form a divalent group, wherein the divalent group is *-C_3-C_8 alkylene-#, *-C_3-C_8 alkenylene-#, *-C_1-C_3 alkylene-C_3-C_8 cycloalkylene-C_1-C_3 alkylene-#, *-C_1-C_3 alkylene-O-C_3-C_6 alkenylene-#, *-C_1-C_3 alkylene-CO-NR_F-C_1-C_3 alkylene-#, *-C_1-C_3 alkylene-NR_F-CO-C_1-C_3 alkylene-#, or *-C_1-C_3 alkylene-3- to 7-membered heterocyclylene-C_1-C_3 alkylene-#, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen and C_1-C_6 alkyl, and R_F is hydrogen or methyl,

* means a point of bonding with the carbon atom to which R_{12} is bonded, and

means a point of bonding with the nitrogen atom to which P_{13} is bonded.

12. The oligopeptide compound or salt thereof, or solvate thereof according to claim 10 or 11, wherein:

P_{12} is methyl; and/or

Q_{12} is hydrogen; and/or

R_{13} is C_2-C_6 alkynyl; C_2-C_6 alkenyloxycarbonylC_1-C_6 alkyl; C_3-C_8 cycloalkyl; C_3-C_8 cycloalkylC_1-C_6 alkyl optionally substituted with one or more halogen atoms; C_7-C_{14} aralkyl optionally substituted with one or more groups selected from the group consisting of halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, C_2-C_6 alkenyloxy, C_2-C_6 alkenyl, C_3-C_8 cycloalkyl, and C_1-C_6 alkylcarbonyl; 5- to 10-membered heteroarylC_1-C_6 alkyl; C_3-C_8 cycloalkoxyC_1-C_6 alkyl; or C_1-C_6 alkoxyC_1-C_6 alkyl; and/or

Q_{13} is hydrogen; and/or

R_{14} is hydrogen; and/or

P_{14} is methyl; and/or

Q_{14} is hydrogen.

13. The oligopeptide compound or salt thereof, or solvate thereof according to any one of claims 10 to 12, wherein:

A_1 is an amino protecting group selected from the group consisting of Fmoc, Boc, Cbz, Alloc, trifluoroacetyl, pentafluoropropionyl, phthaloyl, tosyl, 2-nitrobenzenesulfonyl, 4-nitrobenzenesulfonyl, and 2,4-dinitrobenzenesulfonyl; and/or

A_2 is hydroxy; an -O-carboxyl protecting group, wherein the carboxyl protecting group is selected from the group consisting of a methyl group, an ethyl group, a t-Bu group, a benzyl group, a trityl group, a cumyl group, a methoxytrityl group, a 2-(trimethylsilyl)ethyl group, a 2,2,2-trichloroethyl group, and an allyl group; an amino acid residue supported on a resin for solid-phase synthesis; or a peptide residue supported on a resin for solid-phase synthesis.

14. The oligopeptide compound or salt thereof, or solvate thereof according to any one of claims 10 to 12, wherein A_1 is an amino acid residue and/or a peptide residue, and A_2 is an amino acid residue and/or a peptide residue.

15. The oligopeptide compound or salt thereof, or solvate thereof according to claim 14, wherein A_1 and A_2 are connected.

16. The oligopeptide compound or salt thereof, or solvate thereof according to any one of claims 10 to 15, which has high selectivity for KRAS.

17. The oligopeptide compound or salt thereof, or solvate thereof according to any one of claims 10 to 16, wherein the divalent group that R_{12} and P_{13} together form interacts with His95 of KRAS.

18. The oligopeptide compound or salt thereof, or solvate thereof according to any one of claims 10 to 16, which has KRAS inhibitory activity that is 3 times or more higher than NRAS inhibitory activity and HRAS inhibitory activity.